FDA Publishes Draft Guidance On Psychedelic Drug Research
   By Mike Curley
   The U.S. Food and Drug Administration on Friday published a new draft
   guidance highlighting considerations researchers should take into
   account while investigating the use of psychedelic drugs like
   psilocybin for treatment of medical conditions like depression and
   post-traumatic stress disorder.
    1 document attached
   [1]https://www.law360.com/compliance/articles/1692241?nl_pk=e8718aa1-2a
   dc-4c2d-8e21-50ac9491223a&utm_source=newsletter&utm_medium=email&utm_ca
   mpaign=compliance&utm_content=2023-06-26&nlsidx=0&nlaidx=11

References

   1. https://www.law360.com/compliance/articles/1692241?nl_pk=e8718aa1-2adc-4c2d-8e21-50ac9491223a&utm_source=newsletter&utm_medium=email&utm_campaign=compliance&utm_content=2023-06-26&nlsidx=0&nlaidx=11